NCT07473128
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Recruiting
PHASE3Ages 18+InterventionalSupportive carePharmacosmos A/S
~120 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:TrilaciclibSaline (0.9% NaCl)
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To Compare trilaciclib to placebo on prevention of myelosuppression
Measured over From enrollment and 4 months after
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
Complete recovery from prior anti-tumor surgical procedures
Measurable and evaluable disease through tumor assessment
Willingness to participate and sign informed consent form
Exclusion
Extensive Stage Small Cell Lung Cancer
Active cardiovascular disease
Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
Pregnant or nursing women
What this trial measures
- To Compare trilaciclib to placebo on prevention of myelosuppressionFrom enrollment and 4 months after
Duration and occurrence of severe neutropenia